Announcements
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports First Quarter 2024 Results
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
- Royalty Pharma Declares Second Quarter 2024 Dividend
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
- Royalty Pharma Reports Q4 and Full Year 2023 Results
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
- Royalty Pharma Announces Dividend Increase
More ▼
Key statistics
As of last trade Royalty Pharma PLC (RPD:STU) traded at 25.01, 3.99% above its 52-week low of 24.05, set on Nov 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.01 |
---|---|
High | 25.01 |
Low | 25.01 |
Bid | 24.94 |
Offer | 25.30 |
Previous close | 25.17 |
Average volume | 100.00 |
---|---|
Shares outstanding | 597.44m |
Free float | 385.62m |
P/E (TTM) | 15.33 |
Market cap | 16.33bn USD |
EPS (TTM) | 1.78 USD |
Annual div (ADY) | 0.773 EUR |
---|---|
Annual div yield (ADY) | 3.09% |
Div ex-date | May 16 2024 |
Div pay-date | Jun 14 2024 |
Data delayed at least 15 minutes, as of May 22 2024.
More ▼